Measurable Residual Disease (MRD) Testing - What Is It? Why Is It Done? Ayurvedic Herbs for Cancer Support?

ABSTRACT

Measurable Residual Disease (MRD) testing represents a paradigm shift in oncology from "macro" to "micro" monitoring. Measurable Residual Disease (MRD) testing is an advanced diagnostic approach used to detect extremely small numbers of cancer cells that remain in the body after treatment. It is most commonly applied in blood cancers such as leukaemia, lymphoma, and multiple myeloma. Conventional microscopic examination may show complete remission, but MRD testing can identify one cancer cell among thousands or even millions of healthy cells. This high sensitivity helps physicians evaluate treatment effectiveness, predict relapse, and personalise future therapy plans. Modern MRD techniques include flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). With the growing focus on precision medicine, MRD testing has become an important prognostic and monitoring tool in oncology. This article explores the scientific rigour of MRD, its procedural nuances, and its burgeoning role as the "gold standard" for predicting relapse and tailoring precision medicine in hematologic and solid malignancies.

INTRODUCTION

Cancer treatment aims to eliminate malignant cells completely, yet microscopic residual disease may persist even after successful chemotherapy, radiation, or bone marrow transplantation. These remaining cancer cells can later multiply and lead to disease relapse. Measurable Residual Disease (MRD), previously called Minimal Residual Disease, refers to the small number of cancer cells that survive after treatment and remain undetectable by standard laboratory methods. MRD testing has revolutionised cancer monitoring because it provides deeper insight into remission status than routine blood counts or bone marrow examinations. In haematological malignancies, MRD status is now considered one of the strongest indicators of long-term survival and relapse risk. A patient who is MRD-negative generally has a better prognosis compared to someone who is MRD-positive after therapy.

SCIENTIFIC PRINCIPLE BEHIND THE TEST

The fundamental principle of MRD testing is Targeted Sensitivity. To find a "needle in a haystack," the test must identify unique "signatures" that exist only in cancer cells and not in healthy tissue. This is achieved through two primary scientific avenues:

• Immunophenotyping (Flow Cytometry): Every cell carries a "barcode" of proteins on its surface known as Clusters of Differentiation (CD markers). Cancer cells often express these proteins in abnormal combinations, intensities, or at inappropriate stages of development. By using fluorescently labelled antibodies, scientists can identify these Leukaemia-Associated Immunophenotypes (LAIPs).
• Molecular Genotyping: Cancer is fundamentally a genetic disease. In many blood cancers, the rearrangement of immunoglobulin (Ig) or T-cell receptor (TCR) genes creates a unique DNA sequence for that specific cancer clone. MRD testing clones these sequences and uses them as a molecular "fingerprint." If even a fragment of this fingerprint is found in a sample, the disease is considered present.

KEY COMPONENTS OF THE TEST

The reliability of MRD testing rests on three technological pillars, each offering different depths of "vision":

• Multiparametric Flow Cytometry (MFC): This uses lasers to analyse thousands of cells per second. It identifies cells based on size, complexity, and surface proteins. Modern MFC can reach a sensitivity of 10−4  to 10−5  (one cancer cell in 10,000 to 100,000 cells).
• Quantitative Polymerase Chain Reaction (qPCR): This technique amplifies specific DNA or RNA sequences. It is highly effective when a consistent genetic "error" is present, such as the BCR-ABL1 gene in Chronic Myeloid Leukaemia.
• Next-Generation Sequencing (NGS): The most advanced component, NGS can sequence millions of DNA fragments simultaneously. It offers the highest sensitivity, often reaching 10−6  (one cancer cell in a million).
• Droplet Digital PCR (ddPCR): An emerging tool that partitions a sample into thousands of tiny droplets, allowing for absolute quantification of target DNA molecules without the need for a standard reference curve.

WHAT IS THE PROCEDURE?

The procedure for MRD testing is a highly coordinated chain of events that begins at the patient's bedside and ends in a high-complexity molecular lab.

• Sample Collection: For hematologic malignancies (leukaemias and lymphomas), the sample is usually a bone marrow aspirate, typically taken from the posterior iliac crest (hip bone). In some cases, a high-volume peripheral blood draw is used. For solid tumours, "liquid biopsies" are utilised to detect circulating tumour DNA (ctDNA) in the blood.
• Establishing the Baseline ("Master Template"): Crucially, a sample from the time of initial diagnosis (pre-treatment) is required. This allows the lab to identify the specific "fingerprint" of that patient's cancer. Without this baseline, the lab wouldn't know exactly which mutation or protein pattern to track.
• Laboratory Analysis: In the lab, the sample undergoes intensive preparation. For molecular testing, DNA or RNA is extracted and purified. For flow cytometry, cells are incubated with a cocktail of fluorochrome-conjugated antibodies.
• Computation and Reporting: Sophisticated software filters out the "noise" of healthy cells to find the rare malignant clones. The results are then validated by a hematopathologist or molecular geneticist.

INTERPRETATION OF THE TEST

The results of an MRD test are typically reported as a quantitative ratio or a status relative to a threshold:

• MRD Negative: This means that residual disease is below the Limit of Detection (LOD) of the specific test used (e.g., 10−6). While it doesn't guarantee a 100% cure, it is the strongest possible indicator that the treatment has been highly effective.
• MRD Positive: This indicates that residual cells are still present. Even a "low-level" positive result (e.g., 0.01%) is clinically significant, as it suggests that a relapse is likely unless the treatment plan is adjusted.
• Log Reduction: Clinicians also look at how many "logs" the cancer has dropped. A 3-log reduction means the cancer burden has decreased by 1,000-fold from the starting point.

HEALTH ISSUES WHERE MRD TESTING IS ADVISED

Initially confined to research, MRD is now standard clinical practice for several critical conditions:

• Acute Lymphoblastic Leukaemia (ALL): MRD status is the single most important predictor of outcome in both children and adults. It determines if a patient needs a bone marrow transplant.
• Multiple Myeloma: Achieving MRD negativity is now a primary goal of therapy, often used to decide the duration of maintenance treatment.
• Chronic Myeloid Leukaemia (CML): Used to monitor the effectiveness of Tyrosine Kinase Inhibitors (TKIs) and to determine if a patient can safely stop medication.
• Acute Myeloid Leukaemia (AML): Helps in identifying patients who are at high risk of early relapse despite being in "complete remission."
• Chronic Lymphocytic Leukaemia (CLL): Used after chemo-immunotherapy to predict the duration of the progression-free interval.
• Solid Tumours (Emerging): MRD is being integrated into the treatment of colorectal, lung, and breast cancers to detect "micro-metastases" after surgery.

FACTORS AFFECTING THE RESULTS OF MRD TESTING

Several biological and technical variables can influence the accuracy of the test:

• Hemodilution: If a bone marrow aspirate is contaminated with too much peripheral blood during collection, it can dilute the cancer cells and lead to a "false negative."
• Clonal Evolution: Cancer cells are genetically unstable. During treatment, the original "fingerprint" might change as cells mutate to survive, allowing a new sub-clone to "hide" from the original test parameters.
• The "Patchy" Disease Distribution: In diseases like Multiple Myeloma, cancer cells may live in "pockets" within the bone marrow. A needle might hit a "clean" spot while disease remains elsewhere.
• Assay Sensitivity: A test that can only see 1 in 1,000 cells (10−3) may report "negative", while a more sensitive NGS test at 10−6 would find the disease.

ADVANTAGES OF THE TEST

• Precision Medicine: It allows for "Response-Adapted Therapy." Patients who are MRD-negative may be able to "de-escalate" treatment to avoid toxic side effects, while those who are MRD-positive can "intensify" therapy.
• Early Detection: It can predict a clinical relapse months—or even years—before it becomes visible on an MRI or under a microscope.
• Drug Development: MRD serves as a "surrogate endpoint" in clinical trials, allowing life-saving drugs to be approved faster by demonstrating efficacy at the molecular level.
• Psychological Reassurance: For many patients, knowing they have reached an "MRD-negative" state provides significant mental relief and a clearer outlook on their future.

AYURVEDA INSIGHT

From an Ayurvedic perspective, Measurable Residual Disease (MRD) testing serves as a modern diagnostic window into the Sookshma-Dosha (subtle imbalance), confirming the persistence of Dhatugata-Ama (metabolic toxins) embedded deep within the tissues. Even when gross tumours are eradicated, Ayurveda recognises that the Khavaigunya (vulnerability in the channels) remains, acting as a fertile "soil" where residual malignant Bija (seeds of disease) can survive. MRD-positive status is clinically interpreted as a depletion of Ojas (vitality) and a failure of Agni (metabolic fire) to complete the process of cellular apoptosis and clearance. Consequently, the Ayurvedic strategy shifts from purely destructive measures to Rasayana (rejuvenation) and Srotas-Shodhana (channel purification), aiming to restore the Dhatu-Agni so that the body’s internal environment becomes inhospitable to these lingering cells. By integrating molecular monitoring with traditional protocols to correct the underlying Dosha susceptibility, the objective is to move beyond temporary remission and achieve Punarbhava-Jaya—the total neutralisation of disease recurrence through the sustained restoration of physiological balance.

HERBS USED FOR CANCER MANAGEMENT

1. Kanchnaar (Bauhinia variegata)

In Ayurveda, Kanchnaar is considered useful in managing abnormal tissue growth, glandular swellings, and “Granthi” conditions due to its Kapha-reducing and detoxifying properties. It helps in clearing accumulated toxins (Ama) and supports proper lymphatic circulation. Kanchnaar is commonly used with Guggul in Ayurvedic formulations for balancing aggravated Kapha and Meda dhatu. From a modern perspective, the plant contains flavonoids, tannins, and phenolic compounds with antioxidant and anti-inflammatory properties. These compounds may help reduce oxidative stress and inhibit abnormal cellular proliferation. Its detoxifying and immunomodulatory actions are considered supportive during long-term cancer care.

2. Guggul (Commiphora mukul)

According to Ayurveda, Guggul acts as a powerful “Lekhana” and “Shothahara” herb that helps reduce inflammation, remove toxins, and balance Vata and Kapha doshas. It is traditionally used in conditions involving abnormal masses, swelling, and impaired tissue metabolism. Modern studies suggest that guggulsterones present in Guggul possess anti-inflammatory, antioxidant, and possible antiproliferative effects. These bioactive compounds may influence signalling pathways involved in tumour growth and inflammation. Guggul also supports lipid metabolism and detoxification pathways, which may help improve overall cellular health. Its Rasayana-like activity may contribute to tissue rejuvenation and immune support.

3. Turmeric (Curcuma longa)

Turmeric is highly valued in Ayurveda for its blood-purifying, anti-inflammatory, and wound-healing properties. It helps balance all three doshas and reduces Ama, which is considered a root factor in many chronic diseases. The active compound curcumin has been extensively studied in modern medicine for its antioxidant, anti-inflammatory, and anticancer potential. Curcumin may help regulate cell signalling pathways, suppress abnormal cell growth, and promote programmed cell death (apoptosis). It also helps reduce oxidative stress and inflammatory mediators linked with cancer progression. Turmeric is widely recognised as a supportive herb for enhancing immunity and protecting healthy tissues.

4. Tulsi (Ocimum sanctum)

Tulsi is regarded in Ayurveda as a sacred Rasayana herb that enhances immunity, improves vitality, and protects the body from diseases. It helps pacify Kapha and Vata doshas while supporting respiratory and metabolic health. Modern research shows that Tulsi contains eugenol, ursolic acid, rosmarinic acid, and flavonoids with strong antioxidant and anti-inflammatory properties. These compounds may help protect cells from DNA damage caused by free radicals and environmental toxins. Tulsi also exhibits adaptogenic and immunomodulatory effects that support the body during physical and emotional stress associated with chronic illnesses. Its protective role against oxidative damage makes it beneficial in supportive cancer care.

5. Ashwagandha (Withania somnifera)

Ashwagandha is one of the most important Ayurvedic Rasayana herbs used for strengthening immunity, improving vitality, and restoring body balance. It helps calm aggravated Vata dosha and supports nervous system stability during chronic illness and weakness. Modern studies highlight the role of withanolides, the active compounds in Ashwagandha, which exhibit antioxidant, anti-inflammatory, and potential anticancer activities. These compounds may help inhibit abnormal cell proliferation and support apoptosis in damaged cells. Ashwagandha is also known for reducing stress hormones and improving the overall quality of life in patients undergoing long-term therapies. Its adaptogenic properties help enhance physical strength, resilience, and immune function.

CONCLUSION

Measurable Residual Disease (MRD) testing represents a major advancement in modern oncology by enabling the detection of tiny numbers of residual cancer cells that remain after treatment. Its high sensitivity provides crucial information about treatment response, relapse risk, and long-term prognosis in haematological malignancies. Techniques such as flow cytometry, PCR, and next-generation sequencing have significantly improved the precision of cancer monitoring and personalised therapy planning. As cancer care continues to evolve toward precision medicine, MRD testing is expected to play an even greater role in guiding therapeutic decisions and improving patient outcomes. Combined with comprehensive supportive care and regular monitoring, MRD testing offers a powerful approach for achieving better disease control and long-term survival.